Literature DB >> 29632706

Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.

Edward Cha1, Lawrence Fong1.   

Abstract

CTLA-4 inhibition produces durable T cell-driven antitumor responses, but understanding which patients achieve a long-term benefit remains unclear. Deep sequencing of rearranged T cell receptor β (TCRβ) genes can monitor the effects of CTLA-4 inhibition and potentially identify patients with long-term survival.

Entities:  

Keywords:  CTLA-4; T cell repertoire; immune checkpoint; ipilimumab; next generation sequencing; tremelimumab

Year:  2018        PMID： 29632706      PMCID： PMC5889199          DOI： 10.4161/21624011.2014.956016

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Authors:  Serena S Kwek; Edward Cha; Lawrence Fong
Journal:  Nat Rev Cancer       Date:  2012-03-01       Impact factor: 60.716

2.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

Authors:  Nienke van Rooij; Marit M van Buuren; Daisy Philips; Arno Velds; Mireille Toebes; Bianca Heemskerk; Laura J A van Dijk; Sam Behjati; Henk Hilkmann; Dris El Atmioui; Marja Nieuwland; Michael R Stratton; Ron M Kerkhoven; Can Kesmir; John B Haanen; Pia Kvistborg; Ton N Schumacher
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

3.  Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

Authors:  Lawrence Fong; Serena S Kwek; Shaun O'Brien; Brian Kavanagh; Douglas G McNeel; Vivian Weinberg; Amy M Lin; Jonathan Rosenberg; Charles J Ryan; Brian I Rini; Eric J Small
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

4.  Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

Authors:  Geoffrey Y Ku; Jianda Yuan; David B Page; Sebastian E A Schroeder; Katherine S Panageas; Richard D Carvajal; Paul B Chapman; Gary K Schwartz; James P Allison; Jedd D Wolchok
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

5.  Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Authors:  Edward Cha; Mark Klinger; Yafei Hou; Craig Cummings; Antoni Ribas; Malek Faham; Lawrence Fong
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

6.  Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Authors:  Yong-Chen Lu; Xin Yao; Jessica S Crystal; Yong F Li; Mona El-Gamil; Colin Gross; Lindy Davis; Mark E Dudley; James C Yang; Yardena Samuels; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

7.  CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.

Authors:  Erika von Euw; Thinle Chodon; Narsis Attar; Jason Jalil; Richard C Koya; Begonya Comin-Anduix; Antoni Ribas
Journal:  J Transl Med       Date:  2009-05-20       Impact factor: 5.531

8.  Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Authors:  Begoña Comin-Anduix; Yohan Lee; Jason Jalil; Alain Algazi; Pilar de la Rocha; Luis H Camacho; Viviana A Bozon; Cecile A Bulanhagui; Elisabeth Seja; Arturo Villanueva; Bradley R Straatsma; Antonio Gualberto; James S Economou; John A Glaspy; Jesus Gomez-Navarro; Antoni Ribas
Journal:  J Transl Med       Date:  2008-05-01       Impact factor: 5.531

9.  Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells.

Authors:  Mark Klinger; Katherine Kong; Martin Moorhead; Li Weng; Jianbiao Zheng; Malek Faham
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 10.  Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Authors:  Jedd D Wolchok; F Stephen Hodi; Jeffrey S Weber; James P Allison; Walter J Urba; Caroline Robert; Steven J O'Day; Axel Hoos; Rachel Humphrey; David M Berman; Nils Lonberg; Alan J Korman
Journal:  Ann N Y Acad Sci       Date:  2013-06-17       Impact factor: 5.691
  10 in total
  2 in total

Review 1.  NHS-IL12, a Tumor-Targeting Immunocytokine.

Authors:  John W Greiner; Y Maurice Morillon; Jeffrey Schlom
Journal:  Immunotargets Ther       Date:  2021-05-27

2.  T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.

Authors:  Heleen Vroman; Giulia Balzaretti; Robert A Belderbos; Paul L Klarenbeek; Menno van Nimwegen; Koen Bezemer; Robin Cornelissen; Ilse T G Niewold; Barbera D van Schaik; Antione H van Kampen; Joachim G J V Aerts; Niek de Vries; Rudi W Hendriks
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.